CytoMed Therapeutics Cash Flow Statement 2022-2024 | GDTC

Fifteen years of historical annual cash flow statements for CytoMed Therapeutics (GDTC).

Annual Data | Millions of US $ except per share data

Metric Name
Net Income/Loss
Total Depreciation And Amortization - Cash Flow
Other Non-Cash Items
Total Non-Cash Items
Change In Accounts Receivable
Change In Inventories
Change In Accounts Payable
Change In Assets/Liabilities
Total Change In Assets/Liabilities
Cash Flow From Operating Activities
Net Change In Property, Plant, And Equipment
Net Change In Intangible Assets
Net Acquisitions/Divestitures
Net Change In Short-term Investments
Net Change In Long-Term Investments
Net Change In Investments - Total
Investing Activities - Other
Cash Flow From Investing Activities
Net Long-Term Debt
Net Current Debt
Debt Issuance/Retirement Net - Total
Net Common Equity Issued/Repurchased
Net Total Equity Issued/Repurchased
Total Common And Preferred Stock Dividends Paid
Financial Activities - Other
Cash Flow From Financial Activities
Net Cash Flow
Stock-Based Compensation
Common Stock Dividends Paid
20232022
$-3.13$-2.34
$0.29$0.29
$0.09$0.92
$0.38$1.21
$0$0
$0$0
$0.08$0.19
$0.00$-0.11
$0.08$0.08
$-2.60$-1.04
$-0.04$-0.35
$0$0
$0$0
$-2.10$0
$0$0
$-2.10$0
$0$0
$-2.14$-0.35
$-0.01$-0.01
$-0.25$-0.09
$-0.26$-0.10
$8.57$0.91
$8.57$0.91
$0$0
$-0.04$-0.09
$8.28$0.72
$3.52$-0.70
$0$0
$0$0